I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Equifax Inc (NYSE:EFX) showcases robust revenue growth and operational efficiency in its latest quarterly report. Strategic positioning in credit information services and workforce solutions ...

Week 96 data presented during a late-breaking oral session at EASL 2025 demonstrated the potential of EFX 50mg to reverse cirrhosis in high-need MASH subgroups, including patients with cryptogenic ...

Equifax faces growth headwinds, premium valuation, and flat price action despite AI and cloud investments, with limited ...

Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with ...

EFX is now being further evaluated in three ongoing Phase 3 trials targeting all stages of MASH. EFX, Akero's lead candidate, is an FGF21 analog designed for once-weekly dosing.

Equifax Inc. Annual stock financials by MarketWatch. View the latest EFX financial statements, income statements and financial ratios.

Today we're going to take a look at the well-established Equifax Inc. (NYSE:EFX). The company's stock saw a significant share price rise of 32% in the past couple of months on the NYSE. While good ...